A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

Inclusion criteria

• Documented or suspected diagnosis of chronic pancreatitis or suspected diagnosis of pancreatic cancer.
• Undergoing Endoscopic Procedure.
• Age ≥ 18 years.
• Willing and able to sign informed consent, meeting IRB guidelines.
• Willing and able to meet all study requirements and obligations.

Exclusion criteria

• Ongoing, active pancreatitis at the time of the procedure.
• Known adverse reaction to secretin.
• Recent (within one month) use of medication that can potentially cause pancreatitis, such as metronidazole, tetracycline, sulfonamides.
• Use of anticholinergic medication within 7 days of study.
• Pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception. Acceptable methods of birth control are: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive (started at least one month prior to Visit 1 and continuing for the duration of the trial), contraceptive patch, condoms with spermicide or abstinence.
• Any medical condition which in the judgment of the Principal Investigator makes participation of the patient in the study medically unwarranted.
• Known complete obstruction of the pancreatic duct.
• Patients who have received an investigational product/drug or device within 30 days prior to Visit 1.